TickerSpark Feed

LLY Coverage

Every TickerSpark article mentioning LLY — research reports, earnings, trending movements, and macro context.

2 articles

Eli Lilly (LLY): Incretin Growth Still Drives the Story

Eli Lilly is delivering exceptional revenue and EPS growth, led by Mounjaro and Zepbound, while raising 2026 guidance again. The stock is expensive, but the franchise momentum and pipeline breadth keep the long-term case intact.

Apr 30, 2026·27 min read

Healthcare Drug Manufacturers - General Growth

Trending StockLLY

Eli Lilly and Company (LLY) rises 7.6% on Q1 beat

Eli Lilly and Company (LLY) rises after a strong Q1 2026 beat, a higher full-year outlook, and early launch momentum for its oral GLP-1 obesity pill Foundayo. The rally reflects continued strength in Mounjaro and Zepbound, reinforcing Lilly’s status as a leading growth story in healthcare.

Apr 30, 2026·6 min read

Want a deeper dive on LLY?

Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.

Generate LLY Report